Report error Found 10 Enz. Inhib. hit(s) with all data for entry = 13138
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 150nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 150nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 825nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Nflection Therapeutics
US Patent
Nflection Therapeutics
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:Test compounds in 100% DMSO were screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the sta...More data for this Ligand-Target Pair
